BOSTON, Dec. 9, 2020 /PRNewswire/ -- Stealth
BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology
company focused on the discovery, development and commercialization
of novel therapies for diseases involving mitochondrial
dysfunction, today announced that two abstracts have been selected
for virtual presentations including a poster presentation and a
late breaking research oral presentation at the upcoming
13th International Conference on Cachexia, Sarcopenia
and Wasting Diseases being held online from December 11-13, 2020. The abstracts will feature
encouraging findings from key elamipretide trials, including
MMPOWER-3, highlighting improvements in the six minute walk test in
genetic subgroups with mtDNA replisome disorders, and TAZPOWER,
showing improvement in key biomarkers of mitochondrial dysfunction
to potentially treat skeletal muscle wasting and cardiomyopathies.
The presentations will be available to conference attendees via the
conference website.
Details for the presentations are as follows:
Title: MMPOWER-3 Phase 3 Clinical Trial Results:
Elamipretide improved six-minute walk test in individuals with
mtDNA replisome disorders
Presenter: Michelangelo Mancuso, MD, PhD, University of
Pisa
Session: Late breaking research/trials
Date and Time: Sunday, December 13th,
10:30-11:40 a.m. ET
Title: Changes in Plasma and Urinary Metabolites After
Elamipretide in Barth Syndrome Patients: Analyses from the TAZPOWER
Study
Presenter: Hilary Vernon, MD, PhD, Johns Hopkins University
Abstract #: 8-02
Session: 9. Therapeutic development (clinical) +
Therapeutic development (pre-clinical) I
Date and Time: Saturday, December 12th,
1:55-2:45 p.m. ET
About Stealth
We are a clinical-stage biotechnology company focused on the
discovery, development and commercialization of novel therapies for
diseases involving mitochondrial dysfunction. Mitochondria, found
in nearly every cell in the body, are the body's main source of
energy production and are critical for normal organ function.
Dysfunctional mitochondria characterize a number of rare genetic
diseases and are involved in many common age-related diseases,
typically involving organ systems with high energy demands such as
the heart, the eye, and the brain. We believe our lead product
candidate, elamipretide, has the potential to treat both rare
metabolic cardiomyopathies, such as Barth, Duchenne and Becker
muscular dystrophies and Friedreich's ataxia, rare mitochondrial
diseases entailing nuclear DNA mutations, such as POLG-related
disorders, as well as ophthalmic diseases entailing mitochondrial
dysfunction, such as dry age-related macular degeneration and
Leber's hereditary optic neuropathy. We are evaluating our
second-generation clinical stage candidate, SBT-272, for rare
neurodegenerative disease indications following promising
preclinical data in amyotrophic lateral sclerosis, or ALS. We have
optimized our discovery platform to identify novel
mitochondria-targeted compounds, including SBT-259, the SBT-550
series of compounds, and other compounds which may be nominated as
therapeutic product candidates or utilized as scaffolds to deliver
other compounds to mitochondria.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of
1995. Such forward-looking include statements about the
anticipated completion of the registered direct offering.
Statements that are not historical facts, including statements
about Stealth BioTherapeutics' beliefs, plans and
expectations, are forward-looking statements. The words
"anticipate," "expect," "hope," "plan," "potential," "possible,"
"will," "believe," "estimate," "intend," "may," "predict,"
"project," "would" and similar expressions are intended to identify
forward-looking statements, although not all forward-looking
statements contain these identifying words. Stealth BioTherapeutics
may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not
place undue reliance on these forward-looking statements. Actual
results or events could differ materially from the plans,
intentions and expectations disclosed in the forward-looking
statements as a result of known and unknown risks, uncertainties
and other important factors, including: Stealth BioTherapeutics'
ability to obtain additional funding and to continue as a going
concern; the impact of the COVID-19 pandemic; the ability to
successfully demonstrate the efficacy and safety of Stealth
BioTherapeutics' product candidates and future product
candidates; the preclinical and clinical results for Stealth
BioTherapeutics' product candidates, which may not support
further development and marketing approval; the potential
advantages of Stealth BioTherapeutics' product
candidates; the content and timing of decisions made by
the U.S. FDA, the EMA or other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies, which may affect the initiation, timing
and progress of preclinical studies and clinical trials
of Stealth BioTherapeutics product
candidates; Stealth BioTherapeutics' ability to obtain
and maintain requisite regulatory approvals and to enroll patients
in its planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Stealth
BioTherapeutics' ability to obtain, maintain and enforce
patent and other intellectual property protection for any product
candidates it is developing; and general economic and market
conditions. These and other risks are described in greater detail
under the caption "Risk Factors" included in the Stealth
BioTherapeutics' most recent Annual Report on Form 20-F filed
with the SEC, as well as in any future filings with
the SEC. Forward-looking statements represent management's
current expectations and are inherently uncertain. Except as
required by law, Stealth BioTherapeutics does not
undertake any obligation to update forward-looking statements made
by us to reflect subsequent events or circumstances.
Investor Relations
Stern Investor Relations
Janhavi Mohite, 212-362-1200
IR@StealthBT.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/stealth-biotherapeutics-announces-elamipretide-clinical-data-to-be-presented-at-the-13th-international-conference-on-cachexia-sarcopenia-and-wasting-diseases-301189822.html
SOURCE Stealth BioTherapeutics Inc.